Total Payments
$227,362
2024 Payments
$40,326
Companies
8
Transactions
249
Medicare Patients
314
Medicare Billing
$49,480
Payment Breakdown by Category
Consulting$176,222 (77.5%)
Travel$43,498 (19.1%)
Food & Beverage$6,505 (2.9%)
Research$1,137 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $176,222 | 43 | 77.5% |
| Travel and Lodging | $43,498 | 69 | 19.1% |
| Food and Beverage | $6,505 | 126 | 2.9% |
| Unspecified | $1,137 | 11 | 0.5% |
Payments by Type
General
$226,225
238 transactions
Research
$1,137
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $120,272 | 130 | $0 (2024) |
| Merck Sharp & Dohme LLC | $63,516 | 64 | $0 (2024) |
| Gilead Sciences, Inc. | $22,859 | 27 | $0 (2024) |
| Shionogi Inc | $17,737 | 13 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,691 | 12 | $0 (2018) |
| Theravance Biopharma Inc. | $105.97 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $97.00 | 1 | $0 (2018) |
| BioNTech SE | $84.15 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,326 | 41 | ViiV Healthcare Company ($26,315) |
| 2023 | $40,942 | 41 | Merck Sharp & Dohme LLC ($23,865) |
| 2022 | $12,390 | 12 | ViiV Healthcare Company ($12,390) |
| 2021 | $7,020 | 3 | ViiV Healthcare Company ($5,520) |
| 2020 | $9,101 | 8 | ViiV Healthcare Company ($9,101) |
| 2019 | $38,782 | 53 | ViiV Healthcare Company ($24,518) |
| 2018 | $50,202 | 49 | ViiV Healthcare Company ($26,223) |
| 2017 | $28,599 | 42 | Merck Sharp & Dohme Corporation ($13,401) |
All Payment Transactions
249 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $4,410.00 | General |
| 11/15/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| 11/15/2024 | Shionogi Inc | — | Travel and Lodging | Cash or cash equivalent | $404.43 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $210.17 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $122.14 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $66.85 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $53.35 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $38.57 | General |
| 10/20/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $19.99 | General |
| 10/10/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 10/10/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,782.16 | General |
| 06/13/2024 | ViiV Healthcare Company | CABENUVA (Biological), RUKOBIA | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: HIV | ||||||
| 06/05/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| 04/26/2024 | ViiV Healthcare Company | DOVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $37.55 | General |
| Category: HIV | ||||||
| 04/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: HIV | ||||||
| 04/15/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 04/10/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $28.00 | General |
| 04/05/2024 | ViiV Healthcare Company | — | Travel and Lodging | Cash or cash equivalent | $226.79 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $179.67 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $104.94 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $55.87 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $55.87 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $30.64 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $18.69 | General |
| 03/22/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $9.63 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,035 | 8 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 52 | 97 | $19,252 | $7,547 |
| 2022 | 3 | 72 | 137 | $22,956 | $10,978 |
| 2021 | 4 | 90 | 158 | $31,280 | $15,954 |
| 2020 | 5 | 100 | 155 | $32,800 | $15,001 |
Total Patients
314
Total Services
547
Medicare Billing
$49,480
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 48 | $7,836 | $3,373 | 43.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 18 | $4,968 | $2,138 | 43.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 31 | $6,448 | $2,036 | 31.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 56 | $10,416 | $4,768 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 34 | 66 | $9,240 | $4,617 | 50.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 15 | $3,300 | $1,594 | 48.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 34 | 59 | $12,980 | $6,997 | 53.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 45 | $8,335 | $3,927 | 47.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 27 | 41 | $5,740 | $2,830 | 49.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $4,225 | $2,200 | 52.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 49 | $8,794 | $4,414 | 50.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 25 | 42 | $9,360 | $3,655 | 39.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 20 | $6,480 | $3,502 | 54.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 32 | $4,307 | $1,996 | 46.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 12 | $3,859 | $1,434 | 37.2% |
About Dr. Pablo Tebas, MD
Dr. Pablo Tebas, MD is a Infectious Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659307346.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pablo Tebas, MD has received a total of $227,362 in payments from pharmaceutical and medical device companies, with $40,326 received in 2024. These payments were reported across 249 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($176,222).
As a Medicare-enrolled provider, Tebas has provided services to 314 Medicare beneficiaries, totaling 547 services with total Medicare billing of $49,480. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Philadelphia, PA
- Active Since 06/24/2006
- Last Updated 11/05/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1659307346
Products in Payments
- DELSTRIGO (Drug) $13,050
- RUKOBIA (Drug) $8,602
- DOVATO (Drug) $4,588
- CABENUVA (Biological) $3,726
- MK-1439 (Drug) $2,615
- TRIUMEQ (Drug) $187.00
- VIBATIV (Drug) $105.97
- NO PRODUCT DISCUSSED (Drug) $97.00
- ISENTRESS (Drug) $10.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Philadelphia
Judith Wolf, Md, MD
Infectious Disease — Payments: $1.4M
Infectious Disease $1.4M
Karam Mounzer, Md, MD
Infectious Disease — Payments: $802,727
Infectious Disease $802,727
William Short, Md, MD
Infectious Disease — Payments: $514,722
Infectious Disease $514,722
Ian Frank, Md, MD
Infectious Disease — Payments: $152,592
Infectious Disease $152,592
Lisa Spacek, M.d, M.D
Infectious Disease — Payments: $100,519
Infectious Disease $100,519
Jay Kostman, Md, MD
Infectious Disease — Payments: $81,312
Infectious Disease $81,312